Evidence map›Paper›PMID 37433169›Full record

ArticleBiomedica : revista del Instituto Nacional de Salud2023

Effects of Mimosa caesalpiniifolia pre-formulation on the intestinal barrier during sodium dextran sulfate-induced colitis in Wistar rats

Aline Garnevi-Fávero, Karina Nascimento-da Silva, Willian Rodrigues-Ribeiro, Caroline Marcantonio-Ferreira, Patrícia Sartorelli, Leonardo Cardili, Rita De Cássia-Sinigaglia, Joice Naiara Bertaglia-Pereira, Marcelo Aparecido-da Silva, Wagner Vilegas and 2 more

Open access · diamondAbstract read
In one paragraph

Article in Biomedica : revista del Instituto Nacional de Salud, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Aline Garnevi-FáveroLaboratory of Hepatology Molecular Applied, Discipline of Gastroenterology, Universidade Federal de São Paulo, São Paulo, Brazil. line.garnevi@gmail.com.ORCID 0000-0002-0066-3539
Karina Nascimento-da SilvaLaboratory of Hepatology Molecular Applied, Discipline of Gastroenterology, Universidade Federal de São Paulo, São Paulo, Brazil. karina.nsilva@live.com.ORCID 0000-0002-2349-4686
Willian Rodrigues-RibeiroInstitute of Environmental, Chemistry and Pharmaceutical Sciences, Department of Pharmaceutics Sciences, Universidade Federal de São Paulo, Diadema, Brazil. will.ribeiro181@hotmail.com.ORCID 0000-0001-5080-956X
Caroline Marcantonio-FerreiraInstitute of Environmental, Chemistry and Pharmaceutical Sciences, Department of Pharmaceutics Sciences, Universidade Federal de São Paulo, Diadema, Brazil. caro_valpa@hotmail.com.ORCID 0000-0003-3484-2081
Patrícia SartorelliInstitute of Environmental, Chemistry and Pharmaceutical Sciences, Department of Pharmaceutics Sciences, Universidade Federal de São Paulo, Diadema, Brazil. psartorelli@unifesp.br.ORCID 0000-0002-1624-8145
Leonardo CardiliLaboratory of Experimental and Molecular Pathology, Department of Pathology, Universidade Federal de São Paulo, São Paulo, Brazil. leonardo.cardili@gmail.com.ORCID 0000-0001-9673-4030
Rita De Cássia-SinigagliaElectron Microscopy Centre, Universidade Federal de São Paulo, São Paulo, Brazil. rita.sinigaglia@unifesp.br.ORCID 0000-0001-8747-6316
Joice Naiara Bertaglia-PereiraButantan Institute, São Paulo, Brazil. joice_naiarabp@hotmail.com.ORCID 0000-0003-2609-5450
Marcelo Aparecido-da SilvaPharmacognosy Laboratory, Universidade Federal de Alfenas, Alfenas, Minas Gerais, Brazil. marcelo.silva@unifal-mg.edu.br.ORCID 0000-0002-2169-9346
Wagner VilegasInstitute of Biosciences, São Paulo State University, São Vicente, São Paulo, Brazil . wagner.vilegas@unesp.br.ORCID 0000-0003-3032-2556
Marcelo José Dias-SilvaInstitute of Biosciences, São Paulo State University, São Vicente, São Paulo, Brazil . marcelo.dias@unifal-mg.edu.br.ORCID 0000-0002-2169-9346
Ana Paula Ribeiro-PaiottiLaboratory of Hepatology Molecular Applied, Discipline of Gastroenterology, Universidade Federal de São Paulo, São Paulo, Brazil. a.paiotti@unifesp.br.ORCID 0000-0002-2349-4686
Universidade Federal de São Paulo · BRUniversidade Federal de Alfenas · BRInstituto Butantan · BRUniversidade Estadual Paulista (Unesp) · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionAnti-inflammatories, immunosuppressants, and immunobiological are commonly used in the treatment of inflammatory bowel disease. However, some patients do not present an adequate response or lose effective response during the treatment. A recent study found a potential anti-inflammatory effect of the hydroalcoholic extract of Mimosa caesalpiniifolia on trinitrobenzene sulfonic acid-induced colitis in Wistar rats.

objectiveTo evaluate the effects of M. caesalpiniifolia pre-formulation on the intestinal barrier using dextran sulfate sodium-induced colitis model. MATERIALS AND

methodsLeaf extracts were prepared in 70% ethanol and dried with a Buchi B19 Mini-spray dryer using 20% Aerosil® solution. Thirty-two male Wistar rats were randomized into four groups: basal control, untreated colitis, pre-formulation control (125 mg/kg/day), and colitis treated with pre-formulation (125 mg/kg/day). Clinical activity index was recorded daily and all rats were euthanized on the ninth day. Colon fragments were fixed and processed for histological and ultrastructural analyses. Stool samples were collected and processed for analysis of the short-chain fatty acid.

resultsTreatment with the pre-formulation decreased the clinical activity (bloody diarrhea), inflammatory infiltrate, and the ulcers. Pre-formulation did not repair the epithelial barrier and there were no significant differences in the goblet cells index. There was a significant difference in butyrate levels in the rats treated with the pre-formulation.

conclusionsThe pre-formulation minimized the clinical symptoms of colitis and intestinal inflammation, but did not minimize damage to the intestinal barrier.

Indexed as

ColitisMimosaAnimalsButyratesDextran SulfateMaleRatsRats, WistarButyratesDextran Sulfatecolitisherbal medicineinflammatory bowel diseasesMimosaulcerative

Identifiers

PMID37433169
PMCPMC10552606
OpenAlexW4383957316

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.